The current status and future impact of targeted therapies in non-Hodgkin lymphoma

Expert Review of Hematology

Volumn 6, Issue 2, 2013, Pages 191-203

  Ujjani, Chaitra ^a   Cheson, Bruce D ^a  

^a GEORGETOWN UNIVERSITY   (United States)

Author keywords

antibody drug conjugate; bispecific T cell engager molecules; Hodgkin lymphoma; immunomodulatory agent; monoclonal antibody; non Hodgkin lymphoma; radioimmunotherapy; small molecule kinase inhibitor; targeted therapy

Indexed keywords

ALEMTUZUMAB; BENDAMUSTINE; BLEOMYCIN; BRENTUXIMAB VEDOTIN; CISPLATIN; CYCLOPHOSPHAMIDE; CYTARABINE; CYTOTOXIN; DACARBAZINE; DEXAMETHASONE; DOXORUBICIN; EPRATUZUMAB; FLUDARABINE; IBRITUMOMAB TIUXETAN; IFOSFAMIDE; INOTUZUMAB OZOGAMICIN; MEDI 551; MOGAMULIZUMAB; MONOCLONAL ANTIBODY; OBINUTUZUMAB; OFATUMUMAB; PIDILIZUMAB; PREDNISONE; RADIOISOTOPE; RITUXIMAB; TEMSIROLIMUS; TOSITUMOMAB I 131; UNCLASSIFIED DRUG; UNINDEXED DRUG; VINBLASTINE; VINCRISTINE;

ACUTE GRANULOCYTIC LEUKEMIA; ADVANCED CANCER; ANGIOIMMUNOBLASTIC T CELL LYMPHOMA; AUTOLOGOUS STEM CELL TRANSPLANTATION; B CELL LYMPHOMA; B LYMPHOCYTE; BINDING AFFINITY; BONE MARROW SUPPRESSION; CANCER CHEMOTHERAPY; CANCER FATIGUE; CANCER IMMUNOTHERAPY; CANCER PATIENT; CANCER RADIOTHERAPY; CANCER RECURRENCE; CANCER SURVIVAL; CHEMOTHERAPY INDUCED NAUSEA AND VOMITING; CHRONIC LYMPHATIC LEUKEMIA; DRUG CONJUGATION; DRUG CYTOTOXICITY; DRUG MECHANISM; DRUG SPECIFICITY; DRUG TARGETING; FOLLICULAR LYMPHOMA; HUMAN; INFUSION RELATED REACTION; LARGE CELL LYMPHOMA; LUNG TOXICITY; LYMPHOCYTOMA; MANTLE CELL LYMPHOMA; MOLECULARLY TARGETED THERAPY; MULTICENTER STUDY (TOPIC); MULTIPLE CYCLE TREATMENT; MYELODYSPLASTIC SYNDROME; NEUROPATHY; NEUTROPENIA; NK T CELL LYMPHOMA; NONHODGKIN LYMPHOMA; OVERALL SURVIVAL; PATHOGENESIS; PERIPHERAL T CELL LYMPHOMA; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; RADIOIMMUNOTHERAPY; RANDOMIZED CONTROLLED TRIAL (TOPIC); RASH; REVIEW; T CELL LYMPHOMA; T LYMPHOCYTE; THROMBOCYTOPENIA; TREATMENT OUTCOME;

ANTIBODIES, BISPECIFIC; ANTIBODIES, MONOCLONAL; ANTIGENS, CD20; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; HUMANS; IMMUNOCONJUGATES; IMMUNOLOGIC FACTORS; IMMUNOTHERAPY; IODINE RADIOISOTOPES; LYMPHOMA, NON-HODGKIN; PROTEIN KINASE INHIBITORS;

EID: 84875945486     PISSN: 17474086     EISSN: 17474094     Source Type: Journal    
DOI: 10.1586/ehm.13.6     Document Type: Review

References (96)

1. Wierda WG, Kipps TJ, Mayer J et al .; Hx-CD20-406 Study Investigators. Ofatumumab as single-Agent CD20 immunotherapy in fl udarabine-refractory chronic lymphocytic leukemia. J. Clin. Oncol. 28 (10), 1749-1755 (2010).
2. Wierda WG, Kipps TJ, Dürig J et al .; 407 Study Investigators. Chemoimmunotherapy with O-FC in previously untreated patients with chronic lymphocytic leukemia. Blood 117 (24), 6450-6458 (2011).
3. Hagenbeek A, Gadeberg O, Johnson P et al. First clinical use of ofatumumab, a novel fully human anti-CD20 monoclonal antibody in relapsed or refractory follicular lymphoma: Results of a Phase 1/2 trial. Blood 111 (12), 5486-5495 (2008).
4. Czuczman MS, Fayad L, Delwail V et al .; 405 Study Investigators. Ofatumumab monotherapy in rituximab-refractory follicular lymphoma: Results from a multicenter study. Blood 119 (16), 3698-3704 (2012).
5. Fowler N, Kahanic S, Forero A, et al. Results of a Phase II study with bendamustine and ofatumumab in untreated indolent B-cell non-Hodgkin's lymphoma. Blood (ASH Annual Meeting Abstracts) 118, Abstract 778 (2011).
6. Czuczman M, Viardot A, Hess G, et al Ofatumumab combined with CHOP in previously untreated patients with FL (FL). J. Clin. Oncol. (ASCO Annual Meeting Abstracts) 28 (15), Abstract 8042 (2010).
7. Salles G, Morschhauser F, Lamy T et al. Phase 1 study results of the type II glycoengineered humanized anti-CD20 monoclonal antibody obinutuzumab (GA101) in B-cell lymphoma patients. Blood 119 (22), 5126-5132 (2012).
8. Sehn L, Goy A, Offner F et al. Randomized Phase II trial comparing GA101 (obinutuzumab) with rituximab in patients with relapsed CD20 indolent B-cell non-Hodgkin lymphoma: Preliminary analysis of the GAUSS Study. Blood (ASH Annual Meeting Abstracts) 118, Abstract 269 (2011).
9. Radford J, Davies A, Cartron G et al. Obinutuzumab (GA101) in combination with FC or CHOP in patients with relapsed or refractory FL: Fi nal results of the Phase I GAUDI Study (BO21000). Blood (ASH Annual Meeting Abstracts) 118, Abstract 270 (2011).
10. Dyer M, Grigg A, Dreyling M et al. Obinutuzumab (GA101) in combination with cyclophosphamide, doxorubicin, vincristine and prednisone (CHOP) or bendamustine in patients with previously untreated follicular lymphoma (FL): Results of the Phase Ib GAUDI Study (BO21000). Blood (ASH Annual Meeting Abstracts) 120, Abstract 3638 (2012).
11. Leonard JP, Coleman M, Ketas JC et al. Phase I/II trial of epratuzumab (humanized anti-CD22 antibody) in indolent non-Hodgkin's lymphoma. J. Clin. Oncol. 21 (16), 3051-3059 (2003).
12. Leonard JP, Coleman M, Ketas JC et al. Epratuzumab, a humanized anti-CD22 antibody, in aggressive non-Hodgkin's lymphoma: Phase I/II clinical trial results. Clin. Cancer Res. 10 (16), 5327-5334 (2004).
13. Leonard JP, Schuster SJ, Emmanouilides C et al. Durable complete responses from therapy with combined epratuzumab and rituximab: Fi nal results from an international multicenter, Phase 2 study in recurrent, indolent, non-Hodgkin lymphoma. Cancer 113 (10), 2714-2723 (2008).
14. Grant B, Leonard J, Johnson J et al Combination biologic therapy as initial treatment for FL: Initial results from CALGB 50701-A Phase II trial of extended induction epratuzumab (anti-CD22) and rituximab (anti-CD20). Blood (ASH Annual Meeting Abstracts) 116, Abstract 427 (2010).
15. Micallef IN, Maurer MJ, Wiseman GA et al. Epratuzumab with rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone chemotherapy in patients with previously untreated diffuse large B-cell lymphoma. Blood 118 (15), 4053-4061 (2011).
16. Forero A, Hamadani M, Fanale M et al. MEDI-551, a humanized monoclonal anti-CD19, in adults with relapsed or refractory advanced B-cell malignancies: Results from a Phase 1/2 study. Blood (ASH Annual Meeting Abstracts) 120, Abstract 3677 (2012).
17. Westin J, Chu F, Fayad L et al. Phase II safety and effi cacy study of CT-011, a humanized anti-PD-1 monoclonal antibody, in combination with rituximab in patients with relapsed follicular lymphoma. Blood (ASH Annual Meeting Abstracts) 120, Abstract 793 (2012).
18. Ishida T, Joh T, Uike N et al. Defucosylated anti-CCR4 monoclonal antibody (KW-0761) for relapsed adult T-cell leukemia-lymphoma: A multicenter Phase II study. J. Clin. Oncol. 30 (8), 837-842 (2012).
19. Duvic M, Pinter-Brown L, Foss F et al. Results of a Phase 1/2 study for KW-0761, a monoclonal antibody directed against CC chemokine receptor type 4 (CCR4), in CTCL. Blood (ASH Annual Meeting Abstracts) 116, Abstract 962 (2010).
20. Ishida T, Ogura M, Hatake K et al. Multicenter Phase II study of mogamulizumab (KW-0761), a defucosylated anti-CCR4 antibody, in patients with relapsed peripheral and cutaneous T-cell lymphoma. Blood (ASH Annual Meeting Abstracts) 120, Abstract 795 (2012).
21. Witzig TE, Flinn IW, Gordon LI et al. Treatment with ibritumomab tiuxetan radioimmunotherapy in patients with rituximab-refractory follicular non-Hodgkin's lymphoma. J. Clin. Oncol. 20 (15), 3262-3269 (2002).
22. Kaminski MS, Zelenetz AD, Press OW et al. Pivotal study of iodine I 131 tositumomab for chemotherapy-refractory low-grade or transformed low-grade B-cell non-Hodgkin's lymphomas. J. Clin. Oncol. 19 (19), 3918-3928 (2001).
23. Illidge T, Pettengell R, Bayne M et al Fractionated 90 Y-ibritumomab tiuxetan radioimmunotherapy as an initial therapy of FL. Blood (ASH Annual Meeting Abstracts) 118, Abstract 102 (2011).
24. Kaminski MS, Tuck M, Estes J et al. -tositumomab therapy as initial treatment for follicular lymphoma. N. Engl. J. Med. 352 (5), 441-449 (2005).
25. Morschhauser F, Radford J, Van Hoof A et al. Phase III trial of consolidation therapy with yttrium-90-ibritumomab tiuxetan compared with no additional therapy after fi rst remission in advanced follicular lymphoma. J. Clin. Oncol. 26 (32), 5156-5164 (2008).
26. Press O, Unger J, Rimsza L et al. A Phase III randomized intergroup trial (SWOG S0016) of CHOP chemotherapy plus rituximab vs. CHOP chemotherapy plus 131I-tositumomab for the treatment of newly diagnosed follicular non-Hodgkin's lymphoma. Blood (ASH Annual Meeting Abstracts) 118, Abstract 98 (2011).
27. Smith MR, Li H, Gordon L et al. Phase II study of rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone immunochemotherapy followed by yttrium-90-ibritumomab tiuxetan in untreated mantle-cell lymphoma: Eastern Cooperative Oncology Group Study E1499. J. Clin. Oncol. 30 (25), 3119-3126 (2012).
28. Zevalin ®, Package Insert. Spectr Pharmaceuticals, Inc., CA, USA (2011).
29. Bennett JM, Kaminski MS, Leonard JP et al. Assessment of treatment-related myelodysplastic syndromes and acute myeloid leukemia in patients with non-Hodgkin lymphoma treated with tositumomab and iodine I131 tositumomab. Blood 105 (12), 4576-4582 (2005).
30. Link BK, Martin P, Kaminski MS, Goldsmith SJ, Coleman M, Leonard JP. Cyclophosphamide, vincristine, and prednisone followed by tositumomab and iodine-131-tositumomab in patients with untreated low-grade follicular lymphoma: Eight-year follow-up of a multicenter Phase II study. J. Clin. Oncol. 28 (18), 3035-3041 (2010).
31. Foyil KV, Bartlett NL. Anti-CD30 Antibodies for Hodgkin lymphoma. Curr. Hematol. Malig. Rep. 5 (3), 140-147 (2010).
32. Pro B, Advani R, Brice P et al. Brentuximab vedotin (SGN-35) in patients with relapsed or refractory systemic anaplastic large-cell lymphoma: Results of a Phase II study. J. Clin. Oncol. 30 (18), 2190-2196 (2012).
33. Younes A, Gopal AK, Smith SE et al. Results of a pivotal Phase II study of brentuximab vedotin for patients with relapsed or refractory Hodgkin's lymphoma. J. Clin. Oncol. 30 (18), 2183-2189 (2012).
34. Younes A, Connors J, Park S et al. Frontline therapy with brentuximab vedotin combined with ABVD or AVD in patients with newly diagnosed advanced stage Hodgkin lymphoma. Blood (ASH Annual Meeting Abstracts) 118, Abstract 955 (2011).
35. Fanale M, Shustov A, Forero-Torres A et al. Brentuximab vedotin administered concurrently with multi-Agent chemotherapy as frontline treatment of ALCL and other CD30-positive mature T-cell and NK-cell lymphomas. Blood (ASH Annual Meeting Abstracts) 120, Abstract 60 (2012).
36. Jacobsen EA, Helmers RA, Lee JJ, Lee NA. The expanding role(s) of eosinophils in health and disease. Blood 120 (19), 3882-3890 (2012).
37. Advani A, Coiffi er B, Czuczman MS et al. Safety, pharmacokinetics, and preliminary clinical activity of inotuzumab ozogamicin, a novel immunoconjugate for the treatment of B-cell non-Hodgkin's lymphoma: Results of a Phase I study. J. Clin. Oncol. 28 (12), 2085-2093 (2010).
38. Goy A, Leach J, Ehmann W et al. Inotuzumab ozogamicin (CMC-544) in patients with indolent B-cell NHL that is refractory to rituximab alone, rituximab and chemotherapy, or radioimmunotherapy: Preliminary safety and effi cacy from a Phase 2 trial. Blood (ASH Annual Meeting Abstracts) 116, Abstract 430 (2010).
39. Ogura M, Tsukasaki K, Nagai H et al. Phase I study of BCX1777 (forodesine) in patients with relapsed or refractory peripheral T/natural killer-cell malignancies. Cancer Sci. 103 (7), 1290-1295 (2012).
40. Ogura M, Uchida T, MacDonald DA et al. An open-label, Phase I study of R-CVP in combination with inotuzumab ozogamicin in patients with relapsed/refractory CD22-positive B-cell non-Hodgkin lymphoma. Blood (ASH Annual Meeting Abstracts) 118, 3715 (2011).
41. Younes A, Gordon L, Kim S et al. Phase I multi-dose escalation study of the anti-CD19 maytansinoid immunoconjugate SAR3419 administered by intravenous (IV) infusion every 3 weeks to patients with relapsed/ refractory B-cell non-Hodgkin's lymphoma (NHL). Blood (ASH Annual Meeting Abstracts) 114, Abstract 585 (2009).
42. Palanca-Wessels M, Flinn I, Sehn L et al. A Phase I study of the anti-CD79b antibodyYdrug conjugate (ADC) DCDS4501A targeting CD79b in relapsed or refractory B-cell non-Hodgkin's lymphoma. Blood (ASH Annual Meeting Abstracts) 120, Abstract 56 (2012).
43. Advani R, Lebovic D, Brunvand M et al. A Phase I study of DCDT2980S, an antibodyYdrug conjugate (ADC) targeting CD22, in relapsed or refractory B-cell non-Hodgkin's lymphoma. Blood (ASH Annual Meeting Abstracts) 120, Abstract 59 (2012).
44. Viardot A, Goebeler M, Noppeney R et al. Blinatumomab monotherapy shows effi cacy in patients with relapsed diffuse large B cell lymphoma. Blood (ASH Annual Meeting Abstracts) 118, Abstract 1637 (2011).
45. Nagorsen D, Zugmaier G, Kufer P et al. Transient laboratory fi ndings upon fi rst dosing with T-cell engaging BiTE ® antibody blinatumomab in non-Hodgkin lymphoma patients. Blood (ASH Annual Meeting Abstracts) 114, Abstract 4798 (2009).
46. Topp MS, Gökbuget N, Zugmaier G et al. Long-term follow-up of hematologic relapsefree survival in a Phase 2 study of blinatumomab in patients with MRD in B-lineage ALL. Blood 120 (26), 5185-5187 (2012).
47. Witzig TE, Wiernik PH, Moore T et al. Lenalidomide oral monotherapy produces durable responses in relapsed or refractory indolent non-Hodgkin's Lymphoma. J. Clin. Oncol. 27 (32), 5404-5409 (2009).
48. Leonard J, Jung S, Johnson J et al. CALGB 50401: A randomized trial of lenalidomide alone versus lenalidomide plus rituximab in patients with recurrent FL. J. Clin. Oncol. (ASCO Annual Meeting Abstracts) 30 (15), Abstract 8000 (2012).
49. Fowler H, Neelapu S, Hagemeister F et al. Lenalidomide and rituximab for untreated indolent lymphoma: Fi nal results of a Phase II study. Blood (ASH Annual Meeting Abstracts) 120, Abstract 901 (2012).
50. Habermann TM, Lossos IS, Justice G et al. Lenalidomide oral monotherapy produces a high response rate in patients with relapsed or refractory mantle cell lymphoma. Br. J. Haematol. 145 (3), 344-349 (2009).
51. Morrison V, Jung S. Johnson J et al. Salvage therapy with bortezomib plus lenalidomide for relapsed/refractory mantle cell lymphoma: Initial results of a Phase II trial (Alliance/CALGB 50501). Blood (ASH Annual Meeting Abstracts) 120, Abstract 3696 (2012).
52. Wang M, Fayad L, Wagner-Bartak N et al. Lenalidomide in combination with rituximab for patients with relapsed or refractory mantle-cell lymphoma: A Phase 1/2 clinical trial. Lancet Oncol. 13 (7), 716-723 (2012).
53. Ivanov V, Coso D, Aurran-Schleinitz T et al Potential synergic effect of lenalidomide-rituximab combination: Durable complete remissions in refractory diffuse large B cell lymphoma. Blood (ASH Annual Meeting Abstracts) 118, Abstract 4989 (2011).
54. Nowakowski GS, LaPlant B, Habermann TM et al. Lenalidomide can be safely combined with R-CHOP (R2CHOP) in the initial chemotherapy for aggressive B-cell lymphomas: Phase I study. Leukemia 25 (12), 1877-1881 (2011).
55. Dueck G, Chua N, Prasad A et al. Activity of lenalidomide in a Phase II trial for T-cell lymphoma: Report on the fi rst 24 cases. J. Clin. Oncol. (ASCO Annual Meeting Abstracts) 27 (15), Abstract 8524 (2009).
56. Fehniger T, Larson S, Trinkaus K et al. A Phase 2 multicenter study of continuous dose lenalidomide in relapsed or refractory classical Hodgkin lymphoma. Blood (ASH Annual Meeting Abstracts) 120, Abstract 1623 (2012).
57. Friedberg JW, Sharman J, Sweetenham J et al. Inhibition of Syk with fostamatinib disodium has signifi cant clinical activity in non-Hodgkin lymphoma and chronic lymphocytic leukemia. Blood 115 (13), 2578-2585 (2010).
58. Advani RH, Buggy JJ, Sharman JP et al. Bruton tyrosine kinase inhibitor ibrutinib (PCI-32765) has signifi cant activity in patients with relapsed/refractory B-cell malignancies. J. Clin. Oncol. 31 (1), 88-94 (2013).
59. Fowler N, Advani R, Sharman J et al. The Bruton's tyrosine kinase inhibitor ibrutinib (PCI-32765) is active and tolerated in relapsed follicular lymphoma. Blood (ASH Annual Meeting Abstracts) 120, Abstract 156 (2012).
60. Wang L, Rule S, Martin P et al. Interim results of an international, multicenter, Phase 2 study of Bruton's tyrosine kinase (BTK) inhibitor, ibrutinib (PCI-32765), in relapsed or refractory mantle cell lymphoma (MCL): Durable effi cacy and tolerability with longer follow-up. Blood (ASH Annual Meeting Abstracts) 120, Abstract 904 (2012).
61. Wilson W, Gerecitano J, Goy A et al. The Bruton's tyrosine kinase (BTK) inhibitor, ibrutinib (PCI-32765), has preferential activity in the ABC subtype of relapsed/refractory de novo diffuse large B-cell lymphoma (DLBCL): Interim results of a multicenter, open-label, Phase 2 study. Blood (ASH Annual Meeting Abstracts) 120, Abstract 686 (2012).
62. Byrd J, Furman R, Coutre S et al. The Bruton's tyrosine kinase (BTK) inhibitor ibrutinib (PCI-32765) promotes high response rate, durable remissions, and is tolerable in treatment naive (TN) and relapsed or refractory (RR) chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) patients including patients with high-risk (HR) disease: New and updated results of 116 patients in a Phase Ib/II study. Blood (ASH Annual Meeting Abstracts) 120, Abstract 189 (2012).
63. Jaglowski S, Jones J, Flynn J et al. A Phase Ib/II study evaluating activity and tolerability of BTK inhibitor PCI-32765 and ofatumumab in patients with chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) and related diseases. J. Clin. Oncol. (ASCO Annual Meeting Abstracts) 30 (15), Abstract 6508 (2012).
64. O'Brien S, Barrientos J, Flinn I et al. Combination of the Bruton's tyrosine kinase (BTK) inhibitor PCI-32765 with bendamustine (B)/rituximab (R) (BR) in patients (pts) with relapsed/refractory (R/R) chronic lymphocytic leukemia (CLL): Interim results of a Phase Ib/II study. J. Clin. Oncol. (ASCO Annual Meeting Abstracts). 30 (15), Abstract 6515 (2012).
65. Brown J, Sharman J, Harb W et al. Phase Ib trial of AVL-292, a covalent inhibitor of Bruton's tyrosine kinase (BTK), in chronic lymphocytic leukemia (CLL) and B-non-Hodgkin lymphoma (B-NHL). J. Clin. Oncol. (ASCO Annual Meeting Abstracts) 30 (15), 8032 (2012).
66. Kahl B, Byrd J, Flinn I et al. Clinical safety and activity in a Phase 1 study of CAL-101, an isoform-selective inhibitor of phosphatidylinositol 3-kinase p110δ, in patients with relapsed or refractory non-Hodgkin lymphoma. Blood (ASH Annual Meeting Abstracts) 116, Abstract 1777 (2010).
67. Fowler N, De Vos S, Marshall T et al. Combinations of the phosphatidylinositol 3-kinase-delta (PI3Kδ) inhibitor Gs-1101 (CAL-101) with rituximab and/or bendamustine are tolerable and highly active in previously treated, indolent non-Hodgkin lymphoma: Results from a Phase I study. Blood (ASH Annual Meeting Abstracts) 120, Abstract 3645 (2012).
68. Coutre S, Leonard J, Furman R et al. Combinations of the selective phosphatidylinositol 3-kinase-delta (PI3Kdelta) inhibitor GSY1101 (CAL-101) with rituximab and/or bendamustine are tolerable and highly active in patients with relapsed or refractory chronic lymphocytic leukemia (CLL): Results from a Phase I study. Blood (ASH Annual Meeting Abstracts) 120, Abstract 191 (2012).
69. Meadows SA, Vega F, Kashishian A et al. PI3Kδ inhibitor, GS-1101 (CAL-101), attenuates pathway signaling, induces apoptosis, and overcomes signals from the microenvironment in cellular models of Hodgkin lymphoma. Blood 119 (8), 1897-1900 (2012).
70. Smith SM, van Besien K, Karrison T et al. Temsirolimus has activity in non-mantle cell non-Hodgkin's lymphoma subtypes: The University of Chicago Phase II consortium. J. Clin. Oncol. 28 (31), 4740-4746 (2010).
71. Ansell SM, Inwards DJ, Rowland KM Jr et al. Low-dose, single-Agent temsirolimus for relapsed mantle cell lymphoma: A Phase 2 trial in the North Central Cancer Treatment Group. Cancer 113 (3), 508-514 (2008).
72. Hess G, Herbrecht R, Romaguera J et al. Phase III study to evaluate temsirolimus compared with investigator's choice therapy for the treatment of relapsed or refractory mantle cell lymphoma. J. Clin. Oncol. 27 (23), 3822-3829 (2009).
73. Reeder C, Gornet M, Habermann T et al. A Phase II trial of oral mTOR inhibitor everolimus in relapsed aggressive non-Hodgkin lymphoma. Blood (ASH Annual Meeting Abstracts) 110, Abstract 121 (2007).
74. Johnston P, Pinter-Brown L, Rogerio J et al. Everolimus for relapsed/refractory classical Hodgkin lymphoma: Multicenter, open-label, single-Arm, Phase 2 study. Blood (ASH Annual Meeting Abstracts) 120, Abstract 2740 (2012).
75. Wang M, Popplewell L, Collins R et al. Pillar-1: Multicenter Phase 2 study of everolimus for patients with mantle cell lymphoma who are refractory or intolerant to bortezomib. Blood (ASH Annual Meeting Abstracts) 120, Abstract 2751 (2012).
76. Ansell SM, Tang H, Kurtin PJ et al. Temsirolimus and rituximab in patients with relapsed or refractory mantle cell lymphoma: A Phase 2 study. Lancet Oncol. 12 (4), 361-368 (2011).
77. Hess G, Keller U, Atta J et al Temsirolimus in combination with bendamustine and rituximab for the treatment of relapsed mantle cell and FL. Blood (ASH Annual Meeting Abstracts) 118, Abstract 2697 (2011).
78. Kim S, Kang H, Kim J et al. Phase I study of mTOR inhibitor everolimus plus CHOP in patients with advanced, aggressive T-cell lymphomas. Blood (ASH Annual Meeting Abstracts) 118, Abstract 1642 (2011).
79. Friedberg L, Mahadevan D, Jung J et al. Phase 2 trial of alisertib, an investigational, potent inhibitor of Aurora A kinase in patients with aggressive B and T-cell non-Hodgkin lymphoma. Blood (ASH Annual Meeting Abstracts) 118, Abstract 95 (2011).
80. O'Connor O, Leonard EJ, Benaim E. Phase III study of investigational MLN8237 (alisertib) versus investigator's choice in patients (pts) with relapsed/refractory (rel/ref) peripheral T-cell lymphoma (PTCL). J. Clin. Oncol. (ASCO Annual Meeting Abstracts) 30 (15), TPS8110 (2012).
81. Persky D, Kelly K, Lee P et al. Phase I/II study of investigational agent MLN8237 (alisertib) plus rituximab with or without vincristine in patients (pts) with relapsed/refractory (rel/ref) aggressive diffuse large B-cell lymphoma (DLBCL)/transformed FL (TFL). J. Clin. Oncol. (ASCO Annual Meeting Abstracts) 30 (15), TPS8109 (2012).
82. Tse C, Shoemaker AR, Adickes J et al. ABT-263: A potent and orally bioavailable Bcl-2 family inhibitor. Cancer Res. 68 (9), 3421-3428 (2008).
83. Wilson W, O'Conner O, Czuczman M et al. Phase I/IIa Study of ABT-263 in relapsed or refractory lymphoid malignancies. Blood (ASH Annual Meeting Abstracts) 114, Abstract 1711 (2009).
84. Davids MS, Deng J, Wiestner A et al. Decreased mitochondrial apoptotic priming underlies stroma-ediated treatment resistance in chronic lymphocytic leukemia. Blood 120 (17), 3501-3509 (2012).
85. Seymour J, Davids M, Anderson M et al. The BCL-2-specifi c BH3-mimetic ABT-199 (GDC-0199) is active and well-tolerated in patients with relapsed/refractory chronic lymphocytic leukemia: Interim results of a Phase I fi rst-in-human study. Blood (ASH Annual Meeting Abstracts) 120, Abstract 3923 (2012).
86. Roberts A, Davids M, Mahadevan D et al. Selective inhibition of BCL-2 is active against chronic lymphocytic leukemia CLL: First clinical experience with the BH3-mimetic ABT-199. Haematologica 97, 257-258 Abstract O0546 (2012).
87. Olsen EA, Kim YH, Kuzel TM et al. Phase IIb multicenter trial of vorinostat in patients with persistent, progressive, or treatment refractory cutaneous T-cell lymphoma. J. Clin. Oncol. 25 (21), 3109-3115 (2007).
88. Piekarz RL, Frye R, Turner M et al. Phase II multi-institutional trial of the histone deacetylase inhibitor romidepsin as monotherapy for patients with cutaneous T-cell lymphoma. J. Clin. Oncol. 27 (32), 5410-5417 (2009).
89. Whittaker SJ, Demierre MF, Kim EJ et al. Final results from a multicenter, international, pivotal study of romidepsin in refractory cutaneous T-cell lymphoma. J. Clin. Oncol. 28 (29), 4485-4491 (2010).
90. Piekarz RL, Frye R, Prince HM et al. Phase 2 trial of romidepsin in patients with peripheral T-cell lymphoma. Blood 117 (22), 5827-5834 (2011).
91. Coiffi er B, Pro B, Prince HM et al. Results from a pivotal, open-label, Phase II study of romidepsin in relapsed or refractory peripheral T-cell lymphoma after prior systemic therapy. J. Clin. Oncol. 30 (6), 631-636 (2012).
92. Duvic M, Becker J, Dalle S et al. Phase II trial of oral panobinostat (LBH589) in patients with refractory cutaneous T-cell lymphoma (CTCL). Blood (ASH Annual Meeting Abstracts) 112, Abstract 1005 (2008).
93. Sureda A, Younes A, Ben-Yehuda D et al. Final analysis: Phase II study of oral panobinostat in relapsed/refractory Hodgkin lymphoma patients following autologous hematopoietic stem cell transplant. Blood (ASH Annual Meeting Abstracts) 116, Abstract 419 (2010).
94. Younes A, Copeland A, Fanale M et al. Safety and effi cacy of the novel combination of panobinostat (LBH589) and everolimus (RAD001) in relapsed/refractory Hodgkin and non-Hodgkin lymphoma. Blood (ASH Annual Meeting Abstracts) 118, Abstract 3718 (2011).
95. Christian B, Kopko A, Fehniger TA, Bartlett NL, Blum KA. A Phase I trial of the histone deacetylase (HDAC) inhibitor, panobinostat, in combination with lenalidomide in patients with relapsed/refractory Hodgkin's lymphoma (HL). Blood (ASH Annual Meeting Abstracts) 120, Abstract 1644 (2012).
96. Zhang LH, Kosek J, Wang M, Heise C, Schafer PH, Chopra R. Lenalidomide effi cacy in activated B-cell-like subtype diffuse large B-cell lymphoma is dependent upon IRF4 and cereblon expression. Br. J. Haematol. 160(4), 487-502 (2013).